The Autoimmune Gender Gap
Autoimmune diseases affect women at approximately three times the rate they affect men — a disparity so consistent across conditions and populations that it is clearly biological rather than coincidental. Yet the research investment in autoimmune conditions does not reflect this prevalence, and the clinical community has been slow to integrate sex and gender as variables in autoimmune research design.
Lupus affects women at a nine to one ratio to men. Rheumatoid arthritis affects women at approximately three times the rate of men. Multiple sclerosis affects women at two to three times the rate. Atopic dermatitis, psoriatic arthritis, thyroid conditions — the pattern holds across dozens of conditions.
The Racial Equity Dimension
Lupus is not just a women’s disease — it is, in the United States, disproportionately a Black women’s disease. Black women develop lupus at higher rates, with more severe organ involvement, and with worse outcomes than white women. The research that generates the evidence base for treatment has underrepresented Black women. This is not an abstract equity concern — it is a clinical failure with measurable mortality consequences.
The Cardiovascular Connection
Autoimmune conditions elevate cardiovascular risk through inflammatory pathways that interact with standard risk factors in ways that primary care and cardiology practice have been slow to recognize. Women with rheumatoid arthritis, lupus, or psoriatic arthritis carry a meaningfully elevated risk of heart disease that should inform their preventive care. It frequently does not.
What We Track
We monitor NIH autoimmune research funding, FDA approvals for lupus and rheumatoid arthritis treatments with sex-specific implications, legislative activity on federal autoimmune research investment, and clinical guideline updates from relevant specialty societies.
